Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

NCT03555877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic

Interventions

DRUG: Ribociclib
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Exemestane
DRUG: Fulvestrant

Sponsor

GBG Forschungs GmbH